Endometrial Adenocarcinoma
Showing NaN - NaN of 7
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma Trial in Canton (ACR-368, Gemcitabine,
Recruiting
- Platinum-resistant Ovarian Cancer
- +2 more
- ACR-368
- +2 more
-
Mobile, Alabama
- +7 more
Jan 24, 2023
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States
Active, not recruiting
- Endometrial Adenocarcinoma
- +9 more
- Bevacizumab
- +5 more
-
Phoenix, Arizona
- +232 more
Jan 12, 2023
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,
Recruiting
- Deleterious BRCA1 Gene Mutation
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Aug 23, 2022
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States
Completed
- Endometrial Adenocarcinoma
- +4 more
- Akt Inhibitor MK2206
- Laboratory Biomarker Analysis
-
Boston, Massachusetts
- +6 more
Jan 13, 2022
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma Trial in United States
Completed
- Endometrial Adenocarcinoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Hartford, Connecticut
- +21 more
Oct 13, 2020
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States
Completed
- Endometrial Adenocarcinoma
- +3 more
- Diagnostic Laboratory Biomarker Analysis
- Selumetinib
-
Los Angeles, California
- +71 more
Jul 19, 2019
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in Canada, Hong
Completed
- Endometrial Adenocarcinoma
- +11 more
- Bevacizumab
- +4 more
-
Berkeley, California
- +40 more
Feb 15, 2018